Yuichiro Tada

Department Of Head And Neck Oncology And Surgery
Tokyo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 73 publications

HER2 Intratumoral Heterogeneity in Salivary Duct Carcinoma: Association With Treatment Response and Comparison Between Primary and Metastatic Lesions.

HER2 Intratumoral Heterogeneity in Salivary Duct Carcinoma: Association With Treatment Response and Comparison Between Primary and Metastatic Lesions.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: May 05, 2026

Biomarker-Driven Initial Systemic Therapy Enabling Curative-Intent Treatment in Non-Metastatic Unresectable Salivary Duct Carcinoma: A Multi-Institutional Retrospective Study.

Biomarker-Driven Initial Systemic Therapy Enabling Curative-Intent Treatment in Non-Metastatic Unresectable Salivary Duct Carcinoma: A Multi-Institutional Retrospective Study.

Journal: Head & neck

Published: March 28, 2026

Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 Trial.

Clinical Outcomes of Pembrolizumab in Head and Neck Squamous Cell Carcinoma Subsites Excluded from the KEYNOTE-048 Trial.

Journal: Current oncology (Toronto, Ont.)

Published: December 17, 2025

Effectiveness of Pembrolizumab Monotherapy for Older Adults With Head and Neck Carcinoma by CPS Status.

Effectiveness of Pembrolizumab Monotherapy for Older Adults With Head and Neck Carcinoma by CPS Status.

Journal: Anticancer research

Published: December 16, 2025

Hematological Markers Predict Immune-Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab.

Hematological Markers Predict Immune-Related Adverse Events in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Pembrolizumab.

Journal: Asia-Pacific journal of clinical oncology

Published: July 11, 2025

Palliative systemic therapy for locally advanced or metastatic salivary duct carcinoma: A comprehensive review.

Palliative systemic therapy for locally advanced or metastatic salivary duct carcinoma: A comprehensive review.

Journal: Cancer treatment reviews

Published: April 28, 2025

Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer.

Multicenter phase II trial of trastuzumab and docetaxel for HER2-positive salivary gland cancer.

Journal: Japanese journal of clinical oncology

Published: April 27, 2025

Conversion Surgery After Administration of a TRK Inhibitor for Unresectable Parotid Gland Secretory Carcinoma.

Conversion Surgery After Administration of a TRK Inhibitor for Unresectable Parotid Gland Secretory Carcinoma.

Journal: Head & neck

Published: February 27, 2025

Correlation between basal cell adenoma and basal cell adenocarcinoma of the salivary gland: a histomorphological and molecular review of 129 cases.

Correlation between basal cell adenoma and basal cell adenocarcinoma of the salivary gland: a histomorphological and molecular review of 129 cases.

Journal: Virchows Archiv : an international journal of pathology

Published: February 21, 2025

Cytoplasmic p53 Immunostaining in Salivary Duct Carcinoma: A Poor Prognostic Factor Associated With Characteristic TP53 Variants.

Cytoplasmic p53 Immunostaining in Salivary Duct Carcinoma: A Poor Prognostic Factor Associated With Characteristic TP53 Variants.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: February 17, 2025

12q Amplification Characterizes a Distinctive Salivary Gland Tumor with Bizarre Myoepithelial Atypia.

12q Amplification Characterizes a Distinctive Salivary Gland Tumor with Bizarre Myoepithelial Atypia.

Journal: Head and neck pathology

Published: December 27, 2024

Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.

Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.

Journal: Anticancer research

Published: July 17, 2024

Showing 1-12 of 73

Last Updated: 09/26/2026